Article Details

Iambic begins dosing in trial of IAM1363 for HER2-driven cancer

Retrieved on: 2024-03-28 12:20:56

Tags for this article:

Click the tags to see associated articles and topics

Iambic begins dosing in trial of IAM1363 for HER2-driven cancer. View article details on HISWAI: https://www.clinicaltrialsarena.com/news/iambic-dosing-trial-cancer/

Excerpt

The gold standard of business intelligence. ... The multicentre, open-label, dose escalation and dose optimisation trial aims to assess the tolerability ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up